73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Pacira Pharmaceuticals Inc-DE
Closed
SectorHealthcare
21.69 2.12
Overview
Share price change
24h
Min
20.8
Max
21.97
Income | 10M 5.4M |
|---|---|
Sales | -1.6M 180M |
P/E Sector Avg | 44.83 121.746 |
Profit margin | 3.026 |
Employees | 788 |
EBITDA | 5.1M 34M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +43.95% upside |
Next Earnings | 26 Feb 2026 |
|---|
Market Cap | -91M 906M |
|---|---|
Previous open | 19.57 |
Previous close | 21.69 |
News Sentiment
By Acuity
100%
0%
341 / 352 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Pacira Pharmaceuticals Inc-DE Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pacira Pharmaceuticals Inc-DE Forecast
Price Target
By TipRanks
43.95% upside
12 Months Forecast
Average 30.33 USD 43.95%
High 38 USD
Low 23 USD
Based on 6 Wall Street analysts offering 12 month price targets forPacira Pharmaceuticals Inc-DE - Dist in the last 3 months.
Sentiment
By Acuity
341 / 352 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pacira Pharmaceuticals Inc-DE
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Live chat